1241P Safety monitoring of adjuvant 2 weekly durvalumab for patients with stage III NSCLC: Implications for a 4 weekly regimen during the COVID-19 pandemic and beyond
Under an Elsevier user license
open archive
Cited by (0)
Copyright © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.